|
Zenith News
|
3
|
Zenith Epigenetics
|
May 04, 2020 04:58PM
|
|
Zack's Research Report by Vandermosten dated Aug 2nd, 2017
|
3
|
Resverlogix Corp.
|
Aug 15, 2017 07:22AM
|
|
Violation Report
|
4
|
Resverlogix Corp.
|
Nov 27, 2020 12:50PM
|
|
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
|
6
|
Resverlogix Corp.
|
Aug 29, 2017 01:03PM
|
|
RVX…The Hawthorne Effect
|
4
|
Resverlogix Corp.
|
Oct 01, 2022 11:18AM
|
|
Resverlogix Seeking Partnership for Potential Therapeutic for HIV-1
|
4
|
Resverlogix Corp.
|
Jun 07, 2018 07:57AM
|
|
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
|
4
|
Resverlogix Corp.
|
Feb 23, 2017 07:46AM
|
|
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
3
|
Resverlogix Corp.
|
May 30, 2017 07:54AM
|
|
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
6
|
Resverlogix Corp.
|
Jul 10, 2017 07:53AM
|
|
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
4
|
Resverlogix Corp.
|
Oct 04, 2023 08:44AM
|
|
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
13
|
Resverlogix Corp.
|
Nov 01, 2021 08:34AM
|
|
RESVERLOGIX CORP. Annual And Special Meeting: December 22, 2020
|
2
|
Resverlogix Corp.
|
Nov 25, 2020 07:57AM
|
|
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corpo
|
3
|
Resverlogix Corp.
|
Mar 17, 2017 07:30AM
|
|
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
|
4
|
Resverlogix Corp.
|
Mar 15, 2017 08:09AM
|
|
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
|
6
|
Resverlogix Corp.
|
Nov 12, 2020 08:05AM
|
|
Resverlogix Announces Overnight Marketed Equity Offering
|
1
|
Resverlogix Corp.
|
Jun 08, 2017 04:12PM
|
|
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
|
2
|
Resverlogix Corp.
|
Jun 05, 2017 07:35AM
|
|
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
|
6
|
Resverlogix Corp.
|
Oct 14, 2020 07:35AM
|
|
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
|
5
|
Resverlogix Corp.
|
Jan 18, 2022 08:06AM
|
|
Resverlogix Announces Change in Fiscal Year-End to December 31
|
1
|
Resverlogix Corp.
|
Mar 14, 2021 10:32AM
|
